Revenue reached RMB 4.53 billion, marking a 3.9% year-over-year increase, while R&D expenditure rose by 24.9% to RMB 680 million. The company currently holds RMB 19.4 billion in financial resources, providing a stable runway for its clinical pipeline. A major contributor to the period’s performance was the recognition of RMB 850 million in business development revenue, largely tied to the global licensing deal for SSGJ-707.

Commercial momentum remains anchored in the successful marketing approval of three Class 1 innovative drugs: Yisaituo for psoriasis, NuPIAO for chronic kidney disease, and Yisaina for gout. Looking ahead, 3SBio is preparing to scale its portfolio further, with five additional products currently under New Drug Application review. These candidates target high-growth therapeutic areas, including atopic dermatitis and oncology, as the company seeks to leverage its diversified pipeline to sustain long-term competitive advantages. Beyond clinical milestones, the firm’s commitment to sustainable operations was reflected in a recent upgrade to an 'AA' Wind ESG rating, placing it within the top 3.2% of the global biotechnology sector.